Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WADE THOMAS IAMS

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1134485410
CMS profile
5076219
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$316,496.51

246 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 5 of 5; records 201–246 of 246 matching records. This page contains 46 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WADE THOMAS IAMS

NPI 1134485410 · CMS profile ID 5076219

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–246 of 246 matching records. This page contains 46 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134485410?year=2025&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WADE THOMAS IAMS, NPI 1134485410, CMS profile ID 5076219. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–246 of 246 matching records. This page contains 46 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134485410?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). WADE THOMAS IAMS, NPI 1134485410, CMS profile ID 5076219. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–246 of 246 matching records. This page contains 46 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134485410?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
WADE THOMAS IAMS, NPI 1134485410, CMS profile ID 5076219, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–246 of 246 matching records. This page contains 46 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1134485410?year=2025&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

246 matching records · $316,496.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 246 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–246 of 246.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $224.6103/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226890988 CMS
Amgen Inc. $2,400.0003/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226902081 CMS
Astellas Pharma US Inc $31.3302/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238764386 CMS
Novocure Inc. $106.1402/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251148711 CMS
Novocure Inc. $220.3902/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1251149919 CMS
Novocure Inc. $5,625.0002/25/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1251149921 CMS
Novocure Inc. $441.9602/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1251154689 CMS
Novocure Inc. $589.8302/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1251154691 CMS
Amgen Inc. $354.2402/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226890990 CMS
Merck Sharp & Dohme LLC $125.0202/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238101528 CMS
Amgen Inc. $2,400.0002/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226897766 CMS
Amgen Inc. $67.9602/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226909280 CMS
Amgen Inc. $3,600.0002/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226915097 CMS
AstraZeneca Pharmaceuticals LP $59.9902/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207222219 CMS
Amgen Inc. $125.0002/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228634197 CMS
Janssen Scientific Affairs, LLC $32.9402/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174194769 CMS
Genentech USA, Inc. $2,870.0002/19/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211605973 CMS
Genentech USA, Inc. $87.5502/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211605977 CMS
Genentech USA, Inc. $36.3702/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211605981 CMS
Amgen Inc. $3,430.0002/18/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226878152 CMS
Amgen Inc. $282.0602/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226890978 CMS
Amgen Inc. $183.8602/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226894404 CMS
Amgen Inc. $6,174.0002/18/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226924656 CMS
Novocure Inc. $2,250.0002/11/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1251151053 CMS
CATALYST PHARMACEUTICALS, INC. $850.0002/10/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1253221812 CMS
Dendreon Pharmaceuticals LLC $43.7102/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245002787 CMS
Amgen Inc. $711.7202/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226888725 CMS
Amgen Inc. $437.5702/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226901169 CMS
Regeneron Healthcare Solutions, Inc. $2,493.0001/31/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1212947719 CMS
Amgen Inc. $3,600.0001/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226925448 CMS
Galvanize Therapeutics, Inc $1,200.0001/22/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238407162 CMS
Novocure Inc. $571.9701/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1251147470 CMS
Novocure Inc. $168.0301/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251147472 CMS
Novocure Inc. $5,265.0001/16/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1251149917 CMS
Novocure Inc. $155.1901/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1251154687 CMS
Daiichi Sankyo Inc. $27.2801/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197075225 CMS
JAZZ PHARMACEUTICALS INC. $850.0001/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234300653 CMS
Daiichi Sankyo Inc. $335.9601/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1197087865 CMS
Amgen Inc. $115.9001/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226888037 CMS
Amgen Inc. $2,400.0001/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226892888 CMS
Amgen Inc. $3,600.0001/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226901155 CMS
Amgen Inc. $281.3701/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226904498 CMS
Amgen Inc. $139.1701/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228634203 CMS
Amgen Inc. $124.8101/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228634201 CMS
AstraZeneca Pharmaceuticals LP $103.6501/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206679952 CMS
Amgen Inc. $90.7101/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226913226 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,726.02 4
PY2020 $1,848.64 2
PY2021 $13,670.74 10
PY2022 $53,228.61 38
PY2023 $64,571.63 58
PY2024 $148,596.10 117
PY2025 $316,496.51 246

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,064,974.88 81
PY2024 Principal investigator $504,993.93 28
PY2023 Recipient $111.00 4
PY2023 Principal investigator $1,981,779.15 91
PY2022 Principal investigator $1,071,331.15 89
PY2021 Principal investigator $2,075,142.48 117
PY2020 Principal investigator $940,527.16 122
PY2019 Principal investigator $707,216.34 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,748.00 12/22/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LL
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175421425
Principal investigator 1 Janssen Research & Development, LLC $8,343.00 12/22/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LL
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175421516
Principal investigator 1 Genmab A/S $2,500.00 12/19/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937043
Principal investigator 1 Genmab A/S $5,800.00 12/19/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937062
Principal investigator 1 Genmab A/S $26,500.00 12/19/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937090
Principal investigator 1 Genmab A/S $1,750.00 12/19/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937256
Principal investigator 1 Genentech, Inc. $22,575.00 12/18/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211635443
Principal investigator 1 Genentech, Inc. $18,287.00 12/18/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211635447
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $923.62 11/21/2025 Non-covered Recipient Entity
Tennessee Oncology Centennial Clinic Drug Development Unit
A randomized, openlabel, phase two and phase three study of izalontamab brengitecan compared with platinumbased chemotherapy in patients with epidermal growth factor receptor–mutated nonsmall cell lung cancer whose disease has progressed during treatment with an epidermal growth factor receptor tyrosine kinase inhibitor No dispute reported 06/30/2026 1235993347
Principal investigator 1 Genmab A/S $500.00 11/21/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937070
Principal investigator 1 Genmab A/S $2,000.00 11/21/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937212
Principal investigator 1 Genmab A/S $500.00 11/20/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937098
Principal investigator 1 Genmab A/S $2,000.00 11/20/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937132
Principal investigator 1 Genentech, Inc. $9,702.00 11/18/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211635424
Principal investigator 1 Genentech, Inc. $2,500.00 11/18/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211635434
Principal investigator 1 Genentech, Inc. $4,629.00 11/18/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211635440
Principal investigator 1 Genmab A/S $6,181.00 11/17/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937162
Principal investigator 1 Genmab A/S $4,714.00 11/17/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937190
Principal investigator 1 Genmab A/S $2,000.00 11/17/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937216
Principal investigator 1 Genmab A/S $500.00 11/17/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937236
Principal investigator 1 Merck Sharp & Dohme LLC $62,100.00 11/12/2025 Non-covered Recipient Entity
Tennessee Oncology - Nashville
A Phase 2, Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation No dispute reported 06/30/2026 1232935623
Principal investigator 1 GlaxoSmithKline, LLC. $48.18 11/07/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122737
Principal investigator 1 Genmab A/S $500.00 10/28/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937046
Principal investigator 1 Genmab A/S $2,000.00 10/28/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937166
Principal investigator 1 Genentech, Inc. $10,185.00 10/24/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211635419
Principal investigator 1 Genmab A/S $3,643.00 10/22/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937120
Principal investigator 1 Genmab A/S $4,129.00 10/22/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937146
Principal investigator 1 GlaxoSmithKline, LLC. $182.25 10/16/2025 Non-covered Recipient Entity
ONEONCOLOGY
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122764
Principal investigator 1 Janssen Research & Development, LLC $8,343.00 10/06/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LL
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175421464
Principal investigator 1 Janssen Research & Development, LLC $4,962.00 10/03/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LL
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175421223
Principal investigator 1 Genmab A/S $7,113.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937050
Principal investigator 1 Genmab A/S $7,330.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937074
Principal investigator 1 Genmab A/S $6,178.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937086
Principal investigator 1 Genmab A/S $7,113.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937102
Principal investigator 1 Genmab A/S $3,643.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937111
Principal investigator 1 Genmab A/S $7,330.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937140
Principal investigator 1 Genmab A/S $4,129.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937143
Principal investigator 1 Genmab A/S $8,155.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937150
Principal investigator 1 Genmab A/S $3,643.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937186
Principal investigator 1 Genmab A/S $3,955.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937204
Principal investigator 1 Genmab A/S $3,790.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937208
Principal investigator 1 Genmab A/S $276.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937220
Principal investigator 1 Genmab A/S $3,790.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937232
Principal investigator 1 Genmab A/S $7,330.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937240
Principal investigator 1 Genmab A/S $7,330.00 10/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937244
Principal investigator 1 Janssen Research & Development, LLC $5,149.00 09/15/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LL C
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175421212
Principal investigator 1 Janssen Research & Development, LLC $5,351.00 09/01/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LL C
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175421252
Principal investigator 1 Genentech, Inc. $26,882.00 08/22/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211635403
Principal investigator 1 Genentech, Inc. $19,860.00 08/22/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211635406
Principal investigator 1 Genmab A/S $7,998.00 08/21/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937002
Principal investigator 1 Genmab A/S $3,955.00 08/21/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937009
Principal investigator 1 Genmab A/S $7,330.00 08/21/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937012
Principal investigator 1 Genmab A/S $7,330.00 08/21/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937028
Principal investigator 1 Genmab A/S $276.00 08/21/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235937034
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 08/06/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122744
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 08/06/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122771
Principal investigator 1 GlaxoSmithKline, LLC. $1,400.00 08/06/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122777
Principal investigator 1 Janssen Research & Development, LLC $11,879.00 07/28/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LL C
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175421340
Principal investigator 1 Merck Sharp & Dohme LLC $16,560.00 07/25/2025 Non-covered Recipient Entity
Tennessee Oncology Chattanooga
A Phase 2, Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation No dispute reported 06/30/2026 1232935625
Principal investigator 1 Eli Lilly and Company $114,081.00 06/24/2025 Non-covered Recipient Entity
THE ON EONCOLOGY RESEARCH NETWORK LLC
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187891100
Principal investigator 1 AstraZeneca UK Limited $17,592.16 06/23/2025 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTE
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON) No dispute reported 06/30/2026 1185555417
Principal investigator 1 AstraZeneca Pharmaceuticals LP $83,212.47 06/18/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer No dispute reported 06/30/2026 1185555421
Principal investigator 1 GlaxoSmithKline, LLC. $4,769.97 06/09/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192179937
Principal investigator 1 Eli Lilly and Company $89.02 06/02/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY PLLC
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187892520
Principal investigator 1 Janssen Research & Development, LLC $19,500.00 06/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LL C
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175421321
Principal investigator 1 Janssen Research & Development, LLC $12,575.00 06/02/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LL C
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175421498
Principal investigator 1 AstraZeneca Pharmaceuticals LP $235,360.54 05/28/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 No dispute reported 06/30/2026 1185555419
Principal investigator 1 Eli Lilly and Company $1,905.92 05/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187888180
Principal investigator 1 Genentech, Inc. $37,155.00 05/23/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211635360
Principal investigator 1 Genentech, Inc. $17,295.00 05/23/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211635363
Principal investigator 1 Genentech, Inc. $19,500.00 05/14/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211635390
Principal investigator 1 AstraZeneca UK Limited $10,743.75 04/25/2025 Non-covered Recipient Entity
VANDERBILT HEALTH
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON) No dispute reported 06/30/2026 1185555415
Principal investigator 1 Eli Lilly and Company $3,098.40 04/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187888178
Principal investigator 1 Genentech, Inc. $15,250.00 03/20/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC No dispute reported 06/30/2026 1211635193
Principal investigator 1 GlaxoSmithKline, LLC. $12,000.00 02/28/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122731
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 02/28/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122751
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 02/28/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122758
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 02/28/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192127931
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 02/28/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192179932
Principal investigator 2 AstraZeneca UK Limited $14,888.99 01/14/2025 Covered Recipient Teaching Hospital
Vanderbilt University Medical Center
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON) No dispute reported 06/30/2026 1185555423
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,887.61 01/08/2025 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
AN OPEN-LABEL, PHASE 1, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY OF TAK-676 WITH PEMBROLIZUMAB FOLLOWING RADIATION THERAPY IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER, TRIPLE-NEGATIVE BREAST CANCER, OR SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK THAT HAS PROGRESSED ON CHECKPOINT INHIBITORS No dispute reported 06/30/2026 1223273071